Download Free Medical Anticonvulsants PowerPoint Presentation

Anticonvulsants PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Neurology, which is titled "Anticonvulsants", to know about the Anticonvulsants.

Tags : Neurology, Anticonvulsants

Published on : Aug 23, 2021 | Views : 2121 | Downloads : 10

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Anticonvulsants Charles Nichols, Ph.D. Department of Pharmacology and Experimental Therapeutics cnich1@lsuhsc.edu MEB 5258/5214
Slide 2-

Definitions Convulsion: Sudden attack of involuntary muscular contractions and relaxations. Seizure: Abnormal central nervous system electrical activity. Epilepsy: A group of recurrent disorders of cerebral function characterized by both seizures and convulsions.
Slide 3-

Background Epilepsy: Neurological disorder affecting the CNS. Approximately 2.5 million people in the U.S. (~1% general pop) Cost per patient ranges from $4,272 for persons with remission after initial diagnosis and treatment to $138,602 for persons with intractable and frequent seizures. Causes: Genetic (autosomal dominant genes) Congenital defects Severe head trauma Ischemic injury, tumor Drug abuse Unknown http://www.med.uc.edu/neurology/images/
Slide 4-

Basic Neuroscience Relevant to Seizure Disorders and Epilepsy
Slide 5-

The Brain An extremely complex organ made up of billions of connections between neurons. These connections are each highly controlled and regulated.
Slide 6-

Nerve Cell Communication Neurons communicate between themselves using small molecules called neurotransmitters. These neurotransmitters modulate and regulate the electrical activity of a given neuron, and tell it when to fire an action potential or when not to. Glutamate = excitatory (tells the neuron to fire) GABA = inhibitory (dampens the neuron firing rate) The action potential is an electrical signal that travels down the axon, and is created using sodium ions (Na+), and inhibited by potassium ions (K+). Usually these processes work synergistically to produce normal behavior and activity. When dysfunctional, abnormal electrical activity occurs and can produce seizures.
Slide 7-

Neurotransmitters Sodium Ions/Channels Potassium Ions/Channels Action Potential (Glutamate, GABA)
Slide 8-

Scalp EEG Data Acquisition
Slide 9-

10-second EEGs: Seizure Evolution
Slide 10-

TYPES OF SEIZURES
Slide 11-

Partial (focal) Seizures Excessive electrical activity in one cerebral hemisphere. -Affects only part of the body. Simple Partial: Person may experience a range of strange or unusual sensations. Motor Sensory Autonomic Key feature: preservation of consciousness.
Slide 12-

Partial (focal) Seizures Complex Partial: Loss of awareness at seizure onset. Person seems dazed or confused and exhibits meaningless behaviors. Typically originate in frontal or temporal lobes (e.g. Temporal lobe epilepsy)
Slide 13-

Generalized Seizures Excessive electrical activity in both cerebral hemispheres. Usually originates in the thalamus or brainstem. Affects the whole body. Loss of consciousness is common.
Slide 14-

Generalized Seizures Myoclonic: Brief shock-like muscle jerks generalized or restricted to part of one extremity. Atonic: Sudden loss of muscle tone. Tonic Seizures: sudden stiffening of the body, arms, or legs Clonic Seizures: rhythmic jerking movements of the arms and legs without a tonic component Tonic-clonic (grand mal): Tonic phase followed by clonic phase http://www.nlm.nih.gov/medlineplus/ency/images/ency/fullsize/19076.jpg
Slide 15-

Tonic-Clonic Seizure Can last from one to several minutes Therapeutic intervention = lorazepam injection
Slide 16-

Generalized Seizures Absence (petit mal): Person appears to “blank out” - “Daydreaming” Simple Absence (primarily effects consciousness only) Complex Absence Atypical Absence (Includes physical symptoms like eye blinking or lip movements) Lenox-Glastaut Syndrome. Atypical absence, atonic and myclonic Status Epilepticus: A seizure lasting longer than 30 min, or 3 seizures without a normal period in between May be fatal Emergency intervention required
Slide 17-

Absence Seizure Can last from a second to several minutes
Slide 18-

Incidence of Seizure Types Mayo Clinic Proceedings 1996; 71:576-568
Slide 19-

Seizure Facts Seizures are not usually life threatening. The brain almost always stops the seizure on its own. Breathing may cease for a few seconds, and the patient may turn blue. People don’t feel pain during a seizure; muscles may be sore afterward. Person may be “different” for a while after the seizure.
Slide 20-

Treatment Try to find a cause. (e.g. fever, head trauma, drug abuse) Recurrent seizures that cannot be attributed to any cause are seen in patients with epilepsy. Therapy is aimed at control drugs do not cure. The type of seizure determines the choice of drug! More than 80% of patients with epilepsy can have can have their seizures controlled with medications.
Slide 21-

Treatment Monotherapy with anticonvulsant Increase dose gradually until seizures are controlled or adverse effects become unacceptable. Multiple-drug therapy may be required. Achieve steady-state kinetics Monitor plasma drug levels Avoid sudden withdrawal
Slide 22-

Mechanisms of Action 3 main categories of therapeutics: Inhibition of voltage-gated Na+ channels to slow neuron firing. Enhancement of the inhibitory effects of the neurotransmitter GABA. Inhibition of calcium channels.
Slide 23-

There are Many Adverse Effects of Therapeutics!!!! CNS Effects: Drowsiness, sedation, somnolence Depression Dizziness Slurred speech Ataxia Nystagmus Diploplia Vertigo Headache Confusion Tremor Interference with cognitive functions in learning situations GI Effects Dry Mouth Nausea Vomiting Anorexia Diarrhea Rash Fetal Abnormalities and birth defects
Slide 24-

Anti-convulsant Pharmacotherapy Medications are listed next with general guidelines for use. good first choice, second choice, etc. Actual use will depend more on a combination of your experiences in the clinic and patient individuality and response.
Slide 25-

Na+ Channel Inhibitors
Slide 26-

Na+ Channel Inhibitors Phenytoin (Dilantin, Phenytek): Indications: First choice for partial and generalized tonic-clonic seizures Some efficacy in clonic, myoclonic, atonic, No effect on infantile spasms or absence seizures Drug Interactions: Decreases blood levels of many medications Increases blood levels of phenobarbital & warfarin
Slide 27-

Na+ Channel Inhibitors Phenytoin (Dilantin, Phenytek): Adverse Effects: Hirsutism & coarsening of facial features Acne Gingival hyperplasia (20-40%) Brush teeth >8 times per day A primary reason not to prescribe for children Decreased serum concentrations of folic acid, thyroxine, and vitamin K with long-term use.
Slide 28-

Phenytoin Induced Gingival Hyperplasia 17 year old boy treated with 300mg/day phenytoin for 2 years (unsupervised) Partial recovery at 3 months after discontinuation Images in Clinical Medicine (Feb 2000) 342:325
Slide 29-

Na+ Channel Inhibitors Carbamzepine (Tegretol, Carbatrol): Indications: First choice for complex partial and generalized tonic-clonic seizures. Contraindications: May exacerbate absence or myoclonic seizures. Blood disorders Liver disorders
Slide 30-

Na+ Channel Inhibitors Carbamazepine (Tegretol, Carbatrol): Drug Interactions: CBZ metabolism is affected by many drugs, and CBZ affects the metabolism of many drugs. Adverse Effects: Mild leukopenia or hyponatremia Circulating concentrations of thyroid hormones may be depressed; TSH remains normal.
Slide 31-

Na+ Channel Inhibitors Oxcarbazepine (Trileptal): FDA approved in 2000 for partial seizures Complex partial seizures Primary & secondarily generalized tonic-clonic seizures No effect on absence or myoclonic seizures Fewer adverse effects than CBZ, phenytoin
Slide 32-

Na+ Channel Inhibitors Valproic Acid (Valproate; Depakene, Depakote): Other Mechanisms of Action: 1) Some inhibition of T-type Ca2+ channels. 2) Increases GABA production and decreases GABA metabolism. Indications: Simple or complex partial, & primary generalized tonic-clonic Also used for absence, myoclonic, and atonic seizures. Highly effective for photosensitive epilepsy and juvenile myoclonic epilepsy. Contraindications: Liver disease
Slide 33-

Na+ Channel Inhibitors Valproic Acid (Valproate; Depakene, Depakote): Drug Interactions: Affects metabolism of many drugs through liver enzyme inhibition Phenobarbital “Drunkenness” Clorazepam Prolonged absence seizures
Slide 34-

Na+ Channel Inhibitors Valproic Acid (Valproate; Depakene, Depakote): Adverse Effects: Weight gain (30-50%) Dose-related tremor Transient hair loss Polycystic ovary syndrome and menstrual disturbances Bone loss Ankle swelling
Slide 35-

Na+ Channel Inhibitors Lamotrigine (Lamictal): Other Mechanism of Action: May inhibit synaptic release of glutamate. Indications: Adjunct therapy (ages 2 & up): Simple & complex partial seizures Generalized seizures of Lennox-Gastaut Syndrome Monotherapy (adults): Simple & complex partial seizures Contraindications: May make myoclonic seizures worse.
Slide 36-

Na+ Channel Inhibitors Lamotrigine (Lamictal): Adverse Effects: Rash (10%) Rare progression to serious systemic illness Increased alertness
Slide 37-

Na+ Channel Inhibitors Topiramate (Topamax): Other Mechanism of Action: Enhances post-synaptic GABAA receptor currents. Kainate receptor antagonist (blocks a certain type of glutamate channel) Indications: Adjunct therapy for partial and primary generalized tonic-clonic seizures in adults and children over 2. Decreases tonic and atonic seizures in children with Lennox-Gastaut syndrome. Contraindications: History of kidney stones
Slide 38-

Na+ Channel Inhibitors Topiramate (Topamax): Drug Interactions: CBZ, phenytoin, phenobarbital, & primidone decrease blood levels Adverse Effects: Nervousness & paresthesias Psychomotor slowing, word-finding difficulty, impaired concentration, interference with memory Weight loss & anorexia Metabolic acidosis
Slide 39-

Na+ Channel Inhibitors Zonisamide (Zonegran): Other Mechanism of Action: Inhibits T-type Ca2+ currents. Binds to GABA receptors. Facilitates dopaminergic and serotonergic neurotransmission.
Slide 40-

Na+ Channel Inhibitors Zonisamide (Zonegran): Indications: Approved for adjunct treatment of partial seizures in adults. Appears to have a broad spectrum: Myoclonic seizures Infantile spasms Generalized & atypical absence seizures Lennox-Gastaut Syndrome Drug Interactions: Phenytoin and carbamazepine decrease its half-life by half.
Slide 41-

Na+ Channel Inhibitors Zomisamide (Zonegran): Adverse Effects: Weight loss Abnormal thinking Nervousness Agitation/irritability Usually well tolerated
Slide 42-

Na+ Channel Inhibitors Lidocaine: Only when other drugs are refractory for status epilepticus.
Slide 43-

Enhancement of GABA Inhibition
Slide 44-

Enhancement of GABA Inhibition Barbiturate drugs: Phenobarbital (Luminal) & Primidone (Mysoline): Mechanism of Action: Increases the duration of GABAA-activated Cl- channel opening.
Slide 45-

Enhancement of GABA Inhibition Phenobarbital (Luminal): Indications: Second choice for partial and generalized tonic-clonic seizures. Rapid absorption has made it a common choice for seizures in infants, but adverse cognitive effects cause it to be used less in older children and adults. Status epilepticus Contraindications: Absence Seizures
Slide 46-

Enhancement of GABA Inhibition Primidone (Mysoline): Indications: Adjuvant or monotherapy for partial and generalized tonic-clonic seizures May control refractory generalized tonic-clonic seizures Contraindications: History of porphyria
Slide 47-

Enhancement of GABA Inhibition Phenobarbital (Luminal) & Primidone (Mysoline): Drug Interactions: Other CNS depressants Increased metabolism of vitamin D and K Phenytoin increases the conversion of primidone to phenobarbital.
Slide 48-

Enhancement of GABA Inhibition Phenobarbital (Luminal) & Primidone (Mysoline): Adverse Effects: Agitation and confusion in the elderly. Worsening of pre-existing hyperactivity and aggressiveness in children Sexual side effects Physical dependence
Slide 49-

Enhancement of GABA Inhibition Benzodiazepine drugs: Diazepam (Valium), lorazepam (Ativan), clonazepam (Klonopin), clorazepate (Transxene-SD) Mechanism of Action: Increases the frequency of GABAA-activated Cl- channel opening.
Slide 50-

Enhancement of GABA Inhibition Benzodiazepine drugs: Indications: Only clonazepam & clorazepate approved for long-term treatment. Clorazepate In combination for partial seizures Clonazepam Lennox-Gastaut Syndrome, myoclonic, atonic, and absence seizures Tolerance develops after about 6 months
Slide 51-

Enhancement of GABA Inhibition Benzodiazepine drugs: Indications: Diazepam and lorazepam are used in treatment of status epileticus. Diazepam is painful to inject; lorazepam is more commonly used in acute treatment. Diazepam Intermittent use for control of seizure clusters Diazepam frequently combined with phenytoin.
Slide 52-

Enhancement of GABA Inhibition Benzodiazepine drugs: Contraindications: Diazepam in children under 9 Narrow angle glaucoma Adverse Effects: Hypotonia, Dysarthria Muscle in-coordination (clonazepam) Behavioral disturbances (especially in children) Aggression, Hyperactivity, Irritability and Difficulty concentrating
Slide 53-

Enhancement of GABA Inhibition Tiagabine (Gabitril): Mechanism of Action: Inhibition of GABA transporter (GAT-1) – reduces reuptake of GABA by neurons and glial cells. Indications: Approved in 1998 as an adjunct therapy for partial seizures in patients at least 12 years old. Contraindications: Absence seizures
Slide 54-

Enhancement of GABA Inhibition Tiagabine (Gabitril): Interactions: Blood levels decreased by CBZ, phenytoin, phenobarbital, & primidone Adverse Effects: Asthenia Abdominal pain
Slide 55-

Calcium Channel Blockers
Slide 56-

Voltage-Gated Ca2+ Channel T Currents Ethosuximide (Zarontin): Mechanism of Action: Reduces low threshold Ca2+currents (T currents) in the thalamic neurons. Half-life is ~60 hr in adults; ~30hr in children. Indications: First line for absence seizures Contraindications: May exacerbate partial & tonic-clonic seizures
Slide 57-

Voltage-Gated Ca2+ Channel T Currents Ethosuximide (Zarontin): Adverse Effects: Psychotic behavior Blood dyscrasias Persistent headaches Anorexia Hiccups Lupus-like syndromes Toxicity: parkinson-like symptoms photophobia
Slide 58-

Blockade of Calcium Channels () Gabapentin (Neurontin): Mechanism of Action: Originally designed to be a centrally acting GABA agonist. Selective inhibition of v-g Ca2+ channels containing the α2δ1 subunit. Indications: adjunct therapy in adults and children with partial & secondarily generalized seizures. Also effective as monotherapy.
Slide 59-

Gabapentin (Neurontin): Contraindications: Can exacerbate myoclonic & absence seizures. Adverse Effects: Weight Gain (5%) with ankle edema Irritability Behavioral problems in children (6%) Has been associated with movement disorders. Blockade of Calcium Channels ()
Slide 60-

Pregabalin (Lyrica): Mechanism of Action: Same as gabapentin Indications: Approved in 2005 Adjunct therapy for partial & secondarily generalized seizures Contraindications: No effect on absence, myoclonic, or primary generalized tonic-clonic seizures Other uses: Prescribed for neuropathic pain, fibromyalgia Blockade of Calcium Channels ()
Slide 61-

Other/Unknown MOA Levetiracetam (Keppra): Mechanism of Action: Not exactly known Binding affinity to Synaptic Vesicle Protein 2A correlates with its anticonvulsant activity. Also blocks calcium channel N-currents, increases intracellular Ca2+ levels, modulates GABA channel currents Indications: Approved in 1999 as an adjunct therapy for adults with partial seizures. Some patients have success with monotherapy
Slide 62-

Other/Unknown MOA Levetiracetam (Keppra): Contraindications: Renal dysfunction Adverse Effects: Asthenia Infection Behavioral problems in children
Slide 63-

Other/Unknown MOA Magnesium chloride: Used for magnesium deficiency seizures. Paraldehyde: Alcohol withdrawal seizures.
Slide 64-

Summary
Slide 65-

Na+ Channel Drugs Phenytoin (Dilantin, Phenytek) Cabamazepine (Tegretol, Carbatrol) Valproic Acid (Depakene, Depakote) Lamotrigine (Lamictal) Topiramate (Topamax) Zonisamide (Zonegran) Lidocaine
Slide 66-

GABA Drugs Barbiturates: Phenobarbital (Luminal) Pimidone (Mysoline) Benzodiazepines: Diazepam (Valium) Lorazepam (Ativan) Clonazepam (Klonopin) Clorazepate (Tranxene-SD) Tiagabine (Gabitril) Valproic Acid (Depakene, Depakote) Topiramate (Topamax) Zonisamide (Zonegran)
Slide 67-

Ca2+ Channel Drugs Ethosuximide (Zarontin) Valproic Acid (Depakene, Depakote) Zonisamide (Zonegran) Gabapentin (Neurontin) Pregabalin (Lyrica) Levetiracetam (Keppra)
Slide 68-

Other/Unknown MOA Magnesium chloride Paraldehyde
Slide 69-

Primary Generalized Tonic-Clonic (Grand Mal) Seizures Drugs of Choice: Phenytoin Carbamazepine Oxcarbazepine Valproate Alternatives Lamotrigine Topiramate Zonisamide Levetiracetam Primidone Phenobarbital Diazepam
Slide 70-

Partial, Including Secondarily Generalized Seizures Drugs of Choice: Phenytoin Carbamazepine Oxcarbazepine Valproate Alternatives Lamotrigine Topiramate Zonisamide Levetiracetam Primidone Phenobarbital Gabapentin Pregabalin Tiagabine
Slide 71-

Absence (Petit Mal) Drugs of Choice: Ethosuximide Valproate Alternatives Clonazepam Zonisamide
Slide 72-

Atypical Absence, Myoclonic, Atonic Seizures Drug of Choice: Valproate Alternatives Clonazepam Topiramate Zonisamide Levetiracetam